

Cover Figure

Bone marrow histology of prefibrotic primary myelofibrosis. This figure is taken from the article by Thomas Buhr on page 360.

Hematology News

323 Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemia
Jan Cools

324 DNMT3A and stem cell function: new insights into old pathways
Olga Guryanova and Ross Levine

Editorials and Perspectives

325 The role of antifungal treatment in hematology
Johan A. Maertens, Marcio Nucci, and J. Peter Donnelly

328 Activation of the NOTCH1 pathway in chronic lymphocytic leukemia
Valentina Gianfelici

Original Articles and Brief Reports

Hematopoiesis

331 Oxygen tension plays a critical role in the hematopoietic microenvironment *in vitro*
Duohui Jing, Manja Wobus, David M. Poitz, Martin Bornhäuser, Gerhard Ehninger, and Rainer Ordemann

Red Cell Disorders

340 Ten novel mutations in the erythroid transcription factor *KLF1* gene associated with increased fetal hemoglobin levels in adults
Alice E. Gallienne, Hélène M.P. Dréau, Anna Schuh, John M. Old, and Shirley Henderson

344 Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature
David J. Araten, Rosario Notaro, Howard T Thaler, Nancy Kernan, Farid Boulad, Hugo Castro-Malaspina, Trudy Small, Andromachi Scaradavou, Heather Magnan, Susan Prockop, Sara Chaffee, Jason Gonsky, Raymond Thertulien, Roberto Tarquini, and Lucio Luzzatto

Constitutional Bone Marrow Failure Syndromes

353 Telomere length is associated with disease severity and declines with age in dyskeratosis congenita
Blanche P. Alter, Philip S. Rosenberg, Neelam Giri, Gabriela M. Baerlocher, Peter M. Lansdorp, and Sharon A. Savage

Chronic Myeloproliferative Disorders

360 European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, and Hans Kreipe

366 A risk of essential thrombocythemia in carriers of constitutional *CHEK2* gene mutations
Hanna Janiszewska, Aneta Bał, Maria Pilarska, Marta Heise, Anna Junkiert-Czarnecka, Małgorzata Kuliszkiewicz-Janus, Małgorzata Całbecka, Bożena Jaźwiec, Dariusz Wołowicz, Kazimierz Kuliczkowski, and Olga Haus

Molecular & Cellular Basis of Acute Leukemia

371 Epigenetic inactivation of *TWIST2* in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity
Shabnam H. Thathia, Stuart Ferguson, Hannah E. Gautrey, Sanne D. van Otterdijk, Michela Hili, Vikki Rand, Anthony V. Moorman, Stefan Meyer, Robert Brown, and Gordon Stratthdee

379 Functional analysis of the NUP98-CCDC28A fusion protein
Arnaud Petit, Christine Ragu, Gwendoline Soler, Chris Ottolenghi, Caroline Schluth, Isabelle Radford-Weiss, Sylvie Schneider-Maunoury, Isabelle Callebaut, Nicole Dastugue, Harry A. Drabkin, Olivier A. Bernard, Serge Romana, and Virginie Penard-Lacronique



Official Organ of the
European Hematology Association

Acute Myeloid Leukemia

388 **Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value**
Marta Pratcorona, Saman Abbas, Mathijs A. Sanders, Jasper E. Koenders, François G. Kavelaars, Claudia A.J. Erpelinck-Verschueren, Annelieke Zeilemakers, Bob Löwenberg, and Peter J.M. Valk

393 **A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy**
Michael Lübbert, Björn H. Rüter, Rainer Claus, Claudia Schmoor, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Konstanze Döhner, Anne Hagemeijer, Pierre W. Wijermans, and Hartmut Döhner

Pediatric Acute Lymphoblastic Leukemia

402 **Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome**
Lutz Zeidler, Martin Zimmermann, Anja Möricke, Barbara Meissner, Dorothee Bartels, Christoph Tschan, André Schrauder, Gunnar Cario, Lilia Goudeva, Sarah Jäger, Richard Ratei, Wolf-Dieter Ludwig, Andrea Teigler-Schlegel, Julia Skokowa, Rolf Koehler, Claus R. Bartram, Hansjörg Riehm, Martin Schrappe, Karl Welte, and Martin Stanulla

Hodgkin's Lymphoma

410 **Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma**
Wouter J. Plattel, Anke van den Berg, Lydia Visser, Anne-Marijn van der Graaf, Jan Pruim, Hans Vos, Bouke Hepkema, Arjan Diepstra, and Gustaaf W. van Imhoff

Non-Hodgkin's Lymphoma

416 **Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers**
Francesco Zaja, Stefano De Luca, Umberto Vitolo, Lorella Orsucci, Alessandro Levis, Flavia Salvi, Chiara Rusconi, Erika Ravelli, Alessandra Tucci, Chiara Bottelli, Monica Balzarotti, Ercole Brusamolino, Maurizio Bonfichi, Stefano A. Pileri, Elena Sabattini, Stefano Volpetti, Chiara Monagheddu, Angelo Vacca, Roberto Ria, and Renato Fanin

Chronic Lymphocytic Leukemia

423 **Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach**
Deborah M. Stephens, Amy S. Ruppert, Kristie Blum, Jeffrey Jones, Joseph M. Flynn, Amy J. Johnson, Jia Ji, Mitch A. Phelps, Michael R. Grever, and John C. Byrd

428 **Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials**
CLL Trialists' Collaborative Group (CLLTCG)

437 **NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL**
Ilaria Del Giudice, Davide Rossi, Sabina Chiaretti, Marilisa Marinelli, Simona Tavolaro, Sara Gabrielli, Luca Laurenti, Roberto Marasca, Silvia Rasi, Marco Fangazio, Anna Guarini, Gianluca Gaidano, and Robin Foà

Multiple Myeloma

442 **Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results**
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Peter R.E. Johnson, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Nigel H. Russell, Graham H. Jackson, and J. Anthony Child for the National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group

Graft-Versus-Host Disease

451 **Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study**
Joseph Pidala, Georgia Vogelsang, Paul Martin, Xiaoyu Chai, Barry Storer, Steven Pavletic, Daniel J. Weisdorf, Madan Jagasia, Corey Cutler, Jeanne Palmer, David Jacobsohn, Sally Arai, and Stephanie J. Lee



Official Organ of the
European Hematology Association

Infectious Complications in Hematology

459 Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period
Michelle R. Ananda-Rajah, Andrew Grigg, Maria T. Downey, Ashish Bajel, Tim Spelman, Allen Cheng, Karin T. Thursky, Janette Vincent, and Monica A. Slavin

464 Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach
Manuela Aguilar-Guisado, Almudena Martín-Peña, Ildefonso Espigado, Maite Ruiz Pérez de Pipaon, José Falantes, Fátima de la Cruz, and José M. Cisneros

Letters to the Editor

472 Iron deficiency does not compromise the diagnosis of high HbA2 β thalassemia trait
Cristina Passarello, Antonino Giambona, Monica Cannata, Margherita Vinciguerra, Disma Renda, and Aurelio Maggio

473 Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
Dragana Milojkovic, Amr Ibrahim, Alistair Reid, Letizia Foroni, Jane Apperley, and David Marin

Online-Only Articles

e5 European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. *Haematologica* 2012;97(3):360-5 - *Comment*
Jürgen Thiele, Attilio Orazi, Hans Michael Kvasnicka, Vito Franco, Emanuela Boveri, Umberto Gianelli, Heinz Gisslinger, Francesco Passamonti, Ayalew Tefferi, and Tiziano Barbui

e6 European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. *Haematologica* 2012;97(3):360-5 - *Reply*
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, and Hans Kreipe

Continuing Medical Education

Reproducibility of World Health Organization criteria for discriminating essential thrombocythemia from prefibrotic primary myelofibrosis

Clinical effectiveness of prophylactic voriconazole/posaconazole compared to fluconazole/itraconazole in acute myeloid leukemia/myelodysplastic syndrome

Prognostic value of platelet counts after induction therapy for childhood acute lymphoblastic leukemia

Systematic review of purine analog treatment for chronic lymphocytic leukemia